Earnings summaries and quarterly performance for CHARLES RIVER LABORATORIES INTERNATIONAL.
Executive leadership at CHARLES RIVER LABORATORIES INTERNATIONAL.
James C. Foster
Detailed
Chair, President and Chief Executive Officer
CEO
BG
Birgit Girshick
Detailed
Corporate Executive Vice President and Chief Operating Officer
JW
Joseph W. LaPlume
Detailed
Corporate Executive Vice President, Corporate Development & Strategy
MG
Michael G. Knell
Detailed
Interim Chief Financial Officer
VC
Victoria Creamer
Detailed
Corporate Executive Vice President and Chief People Officer
Board of directors at CHARLES RIVER LABORATORIES INTERNATIONAL.
AC
Abraham Ceesay
Detailed
Director
CB
Craig B. Thompson
Detailed
Director
GL
George Llado, Sr.
Detailed
Director
ME
Mark Enyedy
Detailed
Director
MW
Martin W. Mackay
Detailed
Lead Independent Director
NC
Nancy C. Andrews
Detailed
Director
PG
Paul Graves
Detailed
Director
RK
Reshema Kemps-Polanco
Detailed
Director
SB
Steven Barg
Detailed
Director
VM
Virginia M. Wilson
Detailed
Director
Research analysts who have asked questions during CHARLES RIVER LABORATORIES INTERNATIONAL earnings calls.
CW
Casey Woodring
JPMorgan Chase & Co.
4 questions for CRL
Also covers: A, BLLN, HOLX +10 more
DW
David Windley
Jefferies Financial Group Inc.
4 questions for CRL
Also covers: CERT, CNC, CTLT +14 more
Elizabeth Anderson
Evercore ISI
4 questions for CRL
Also covers: AGL, ALGN, CAH +23 more
MS
Max Smock
William Blair & Company
4 questions for CRL
Also covers: CDMO, CERT, CTLT +7 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for CRL
Also covers: A, ALGN, AVTR +28 more
Patrick Donnelly
Citi
4 questions for CRL
Also covers: A, AVTR, BIO +21 more
CR
Charles Rhyee
TD Cowen
3 questions for CRL
Also covers: AMWL, BTSG, CAH +18 more
EC
Eric Coldwell
Robert W. Baird & Co.
3 questions for CRL
Also covers: AHCO, CAH, COR +9 more
JB
Justin Bowers
Deutsche Bank AG
3 questions for CRL
Also covers: AMED, CON, CTLT +9 more
TS
Tejas Savant
Morgan Stanley
3 questions for CRL
Also covers: ADPT, AKYA, AVTR +19 more
AH
Ann Hynes
Mizuho Financial Group
2 questions for CRL
Also covers: ARDT, BTSG, CI +17 more
Joshua Waldman
Cleveland Research Company
2 questions for CRL
Also covers: A, BRKR, ICLR +1 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for CRL
Also covers: A, ADPT, AVTR +21 more
AK
Anna Kruszenski
Barclays
1 question for CRL
Also covers: CERT
DL
Daniel Leonard
Stifel Financial Corp.
1 question for CRL
Also covers: A, AVTR, BIO +15 more
JJ
Jacob Johnson
Stephens Inc.
1 question for CRL
Also covers: AZTA, CDMO, CDXS +11 more
KC
Kyle Cruise
UBS
1 question for CRL
Also covers: WST
Luke Sergott
Barclays
1 question for CRL
Also covers: A, AVTR, BRKR +19 more
MS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for CRL
Also covers: CTKB, MRVI, NTRA +4 more
Recent press releases and 8-K filings for CRL.
Charles River Labs outlines 2026 outlook and strategic moves at JPM Healthcare Conference
CRL
Guidance Update
M&A
CEO Change
- Charles River reported a preliminary Q4 Discovery & Safety Assessment (DSA) net book-to-bill of 1.1×, driven by stronger small/mid-biotech bookings, and reiterated that H2 2026 organic revenue growth should be at least flat on both consolidated and DSA bases.
- Management announced two acquisitions: a ~$500 million Cambodian non-human primate supplier (projected EPS accretion of $0.25 in 2026 and $0.60 in 2027) and a $60 million exercise to acquire PathoQuest to bolster non-animal testing capabilities.
- The company is divesting non-performing businesses (≈7% of revenue), targeting completion by end of Q1 2026, and has a plan to deliver $300 million of annualized cost savings.
- CEO Jim Foster will retire at the May 5, 2026 annual meeting, with COO (35-year veteran) set to succeed him; a new board committee will oversee non-animal technologies strategy.
4 days ago
Charles River Labs outlines strategy, M&A, and leadership transition
CRL
M&A
Guidance Update
CEO Change
- Strategic portfolio reshaping: divestiture of
7% non-core revenue by end of Q1 2026; target $300 M in annualized cost savings; announced acquisitions of a Cambodian NHP supplier ($500 M) and PathoQuest (~$60 M) to secure supply and advance non-animal technologies, with $0.25 EPS accretion in 2026 and $0.60 in 2027. - Demand recovery in Discovery & Safety Assessment: Q4 DSA net book-to-bill at 1.1× driven by small/mid-cap biotech amid improved venture funding; 2026 organic revenue growth outlook flat at the top end of guidance range.
- Strong operational and financial position: LTM revenue of ~$4 B, with 66% in North America and 27% in Europe; improving free cash flow and operating margins despite recent sales declines; leverage reduced to 2.1×.
- Leadership transition: CEO Jim Foster to retire May 5, 2026, succeeded by current COO; governance update includes a new lead independent director as board chair.
4 days ago
Charles River Labs outlines 2026 strategy and outlook at JPM Healthcare Conference
CRL
M&A
Guidance Update
CEO Change
- Charles River Labs is a $4 billion LTM revenue non-clinical CRO, operating in three segments: research models (~20%), discovery & safety assessment (~60%), and manufacturing solutions (~20%).
- Announced two M&A deals: acquisition of a Cambodian non-human primate supplier for ≈$500 million, accretive to EPS by $0.25 in 2026 and $0.60 in 2027; and exercised option to buy PathoQuest (NAMs) for ≈$60 million.
- Preliminary 4Q DSA net book-to-bill of 1.1×, driven by small/mid-size biotech; 2026 outlook assumes organic revenue growth of up to flat at the top end for both consolidated and DSA businesses.
- CEO succession: James Foster to retire at the annual meeting on May 5, with the long-serving COO succeeding him as CEO and the lead independent director becoming board chair.
- Strengthening non-animal technologies (NAMs): $200 million annual NAMs revenue, appointment of a former FDA deputy commissioner as Chief Scientific & Innovation Officer, and a dedicated board committee on NAMs.
4 days ago
Charles River Laboratories outlines 2026 outlook and M&A plans at J.P. Morgan Conference
CRL
M&A
Guidance Update
- 2026 outlook: organic revenue growth expected to be at least flat for both consolidated and DSA segments, with a return to growth in 2H26; FX projected to add 100–150 bps to reported revenue growth (LTM 4Q25).
- M&A update: agreement to acquire K.F. (Cambodia) for ~$510 M, closing early 1Q26 with non-GAAP EPS accretion of ~$0.25 in 2026 and ~$0.60 in 2027; exercising option to buy remaining 79% of PathoQuest SAS for ~$60 M, adding $15–20 M of revenue in 2026.
- Financial performance: 2024 revenue of $4,050 M and LTM 2025 revenue of $4,024 M; LTM 2025 operating cash flow of $749 M and non-GAAP operating margin of 20.2%.
- Cost savings: targeting $295 M of cumulative annualized savings by 2026, including $70 M announced in November 2025 to improve operating efficiency.
- Capital allocation: reauthorized $1 B share repurchase in October 2025 and repurchased ~$450 M in 2024–2025; maintained gross/net leverage at 2.1x as of Q3 2025.
4 days ago
Charles River Laboratories announces Q4 2025 DSA trends and acquisition plans
CRL
Guidance Update
M&A
- In Q4 2025, DSA net book-to-bill was approximately 1.1x, reflecting improved demand trends during H2 2025.
- 2026 outlook: expects organic revenue growth at the top end of guidance (flat) for both consolidated and DSA segments, with FX providing 100–150 bps tailwind; anticipates return to revenue growth in H2 2026.
- Plans > $100 M in incremental cost savings to support non-GAAP operating margins in 2026, before considering upcoming transactions.
- Agreed to acquire K.F. (Cambodia) Ltd. for ~$510 M, closing early Q1 2026; accretive to non-GAAP EPS by $0.25 in 2026 and $0.60 in 2027.
- Exercised option to buy remaining 79% of PathoQuest SAS for €51.6 M (~$60 M), closing by end Q1 2026; expected 2026 revenue of $15–20 M, with no material impact on 2026/2027 results.
5 days ago
Charles River Laboratories announces planned acquisitions and 2026 outlook
CRL
M&A
Hiring
Guidance Update
- Planned acquisition of K.F. (Cambodia) Ltd. for $510.0 million, expected to close early Q1 2026, accretive to non-GAAP EPS by ~$0.25 in 2026 and ~$0.60 in 2027
- Exercised option to acquire remaining 79% of PathoQuest SAS for €51.6 million (~$60 million), expected to close by end Q1 2026; PathoQuest projected to generate $15–20 million in 2026 revenue
- Appointed Dr. Namandjé N. Bumpus as Senior VP, Chief Scientific and Innovation Officer to drive scientific strategy and innovation
- Reported DSA net book-to-bill of ~1.1x in Q4 2025 and issued preliminary 2026 outlook: top-end organic revenue growth at least flat, with an FX benefit of 100–150 bps and expected segment growth in H2 2026
5 days ago
Charles River Laboratories announces CEO succession plan
CRL
CEO Change
Board Change
- James C. Foster, Chair, President & CEO, will retire effective May 5, 2026 at the conclusion of the 2026 Annual Meeting of Shareholders.
- The Board has unanimously appointed Birgit Girshick, current Executive Vice President & COO, as the next CEO, also effective in May 2026.
- Foster will remain on the Board as a non-executive director, and Lead Independent Director Martin Mackay will become Chair, separating the Chair and CEO roles.
- During Foster’s 30+ years as CEO, Charles River transformed into a leading preclinical CRO, achieving $4 billion in annual revenue and joining the S&P 500.
Jan 8, 2026, 1:00 PM
Charles River Labs outlines strategic divestitures and NAMs investment
CRL
M&A
New Projects/Investments
Demand Weakening
- Sequential improvement in book-to-bill since Q3, driven by an uptick in biotech funding (second-best month ever) and stable pharma demand under long-term contracts.
- Plans to divest ~7% of non-core revenue, with proceeds targeted for M&A in lab services/bioanalysis, NAMs technologies, and potential China expansion.
- Investing in lab services growth and targeting $70 million of efficiency savings through labor optimization, procurement improvements, offshoring, and automation.
- Expanding NAMs portfolio via internal initiatives and targeted acquisitions, while leveraging FDA guidance easing long-term NHP requirements for monoclonal antibody studies to accelerate discovery tools.
- Upgraded CDMO facilities now support additional cell- and gene-therapy capacity, and the microbial LAL testing business remains a high-margin, IP-protected cornerstone.
Dec 3, 2025, 3:00 PM
Charles River outlines strategic priorities at Evercore HealthCONx conference
CRL
Demand Weakening
M&A
Hiring
- Book-to-bill has improved sequentially since the start of Q3, supported by stable pharma demand via multi-year contracts and a rebound in biotech funding, with October as the second-best funding month ever.
- Lab services (DSA) sees targeted hiring and investments in procurement efficiency, offshoring, and automation to drive $70 M of margin improvement in 2026.
- Non-core asset divestiture (~7% of revenue) is underway, with proceeds earmarked for M&A, debt reduction, or share buybacks.
- NAMs strategy with $200 M in current revenue focuses on acquiring practical non-animal in vitro technologies for discovery; minimal near-term impact on safety testing beyond monoclonal antibodies.
- Geographic expansion considerations include re-entering the China market and bolstering bioanalysis and lab services to capitalize on local innovation and cost-sensitive workflows.
Dec 3, 2025, 3:00 PM
Charles River highlights improving book-to-bill, divestiture and investment plans
CRL
Demand Weakening
M&A
- Sequential improvement in book-to-bill since the start of Q3 2025, buoyed by second-best monthly biotech funding ever and stable pharma demand, although biotech remains the primary headwind tied to capital access.
- Plans to divest ~7% of revenue in non-core assets following a deep portfolio review, with proceeds targeted for strategic M&A, debt reduction, or share repurchases.
- Accelerating lab services (bioanalysis) growth through organic hiring and potential M&A to expand large-molecule bioanalysis and high-throughput clinical sample capabilities.
- Evaluating non-animal methods (NAMs) and geographic expansion (Europe, China) via dedicated internal and board committees, expecting NAMs to drive discovery enhancements but minimal near-term impact on safety testing.
- Manufacturing segment (CDMO) shows upgraded facilities and regulatory compliance, yet faces demand softness in clinical manufacturing; microbial (LAL) testing remains a high-margin, stable business.
Dec 3, 2025, 3:00 PM
Quarterly earnings call transcripts for CHARLES RIVER LABORATORIES INTERNATIONAL.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more